R-Alpha Lipoic Acid.

Pyruvate and alpha-ketoglutarate dehydrogenase both need thiamine pyrophosphate to decarboxylate the substrate and a lipoamide arm to accept what is left. The two cofactors work in sequence inside the same complex.

Dihydrolipoyl dehydrogenase uses FAD, made from riboflavin, to return the reduced lipoamide arm to its working form. Without it the lipoic acid cofactor stays reduced and the cycle stalls.

Coenzyme A, built from pantothenic acid, takes the acetyl group that the lipoamide arm hands over. It is the next station in the same reaction sequence.

NAD+ derived from niacin accepts the electrons passed from the reduced lipoamide arm through FAD. The four cofactors form one chain in the dehydrogenase complexes.

Carnitine carries fatty acids into the mitochondrion and lipoic acid is the cofactor for the complexes that oxidise the resulting acetyl units. The two act on consecutive steps of the same route.

Dihydrolipoic acid, the reduced form of lipoic acid, hands electrons back to oxidised ascorbate and returns it to its active form. This is the textbook antioxidant recycling network.

Tocopherol in the membrane is regenerated by ascorbate, which in turn is regenerated by dihydrolipoic acid. Lipoic acid therefore sits upstream of vitamin E in the same recycling chain.

Dihydrolipoic acid reduces oxidised glutathione back to its active form and improves cysteine availability for new glutathione synthesis. Both effects push in the same direction.

NAC supplies the rate-limiting cysteine for glutathione synthesis while lipoic acid keeps existing glutathione in the reduced form. One builds the pool and the other maintains it.

Dihydrolipoic acid can reduce ubiquinone back to ubiquinol, the form that acts as a lipid antioxidant. The pairing keeps the mitochondrial carrier in its reduced state.

Thioredoxin reductase, a selenium-dependent enzyme, is one of the systems that reduces lipoic acid to dihydrolipoic acid inside the cell. Selenium status therefore affects how much of the active reduced form is generated.

Lipoic acid and biotin are both carried by the sodium-dependent multivitamin transporter, so a large lipoic acid intake competes with biotin uptake at that carrier. Formulas pairing high dose lipoic acid usually include biotin for that reason.

The dithiolane ring of lipoic acid binds transition metals, so taking it in the same dose as an iron salt can reduce how much of the mineral is taken up. Separating the doses avoids the interaction.

Benfotiamine raises thiamine pyrophosphate for transketolase and the dehydrogenase complexes, the same complexes where lipoic acid is the swinging arm. The two act on adjacent points of glucose oxidation.

Alpha-lipoic acid is commonly co-formulated with a B complex that includes pyridoxine, and that combination has been evaluated as a single oral preparation for nerve-related endpoints. Pyridoxal-5-phosphate is a cofactor in amino acid and neurotransmitter metabolism, which is the stated rationale for combining it with a mitochondrial cofactor. The evidence is for the combination product rather than for either component alone.

Cobalamin is the third component of the B complex preparations that are routinely paired with alpha-lipoic acid in clinical evaluations of nerve function. It is required for methylmalonyl-CoA mutase and for methionine synthase, both upstream of normal nerve maintenance. As with the other B vitamins, the trial evidence attaches to the fixed combination, not to lipoic acid plus cobalamin specifically.

Alpha-lipoic acid, betaine and L-carnitine have been fed together in mice with gut microbiota composition and body fat markers as endpoints. Betaine is a methyl donor in homocysteine remethylation and lipoic acid works in mitochondrial oxidative decarboxylation, so the two occupy different parts of energy and one-carbon metabolism. The finding is non-human and describes markers, not outcomes.

Carnitine shuttles long-chain fatty acids into the mitochondrial matrix, and lipoamide-dependent dehydrogenase complexes handle the pyruvate and branched-chain ketoacid entry points to the same matrix. Feeding the two together, with betaine, has been examined in mice. The mechanistic pairing is settled biochemistry; the combination data are non-human.

A poultry feeding study combined nano-encapsulated probiotics with alpha-lipoic acid and reported blood parameters, immune measures and gut health measures. Any read-across to human supplementation is speculative. The row records that the pairing has been examined at all, in birds, and nothing more.

Both compounds sit in the mitochondrial redox network, ubiquinone as the mobile electron carrier of the inner membrane and lipoamide as the swinging arm of the dehydrogenase complexes feeding it. The two are measured together in serum redox panels because they report on overlapping chemistry. Serum concentration is a marker, not an outcome.

The reduced dihydrolipoic form carries two adjacent thiol groups and binds transition metals including copper. That chelating capacity is part of why lipoic acid limits metal-catalysed lipid oxidation, and it also means large doses can interact with mineral supply taken at the same time. Separating a mineral dose from a large lipoic acid dose is the usual formulation response.

Dihydrolipoic acid binds divalent metal ions through its two thiol groups, and zinc is among them. The practical effect is on how much of a co-administered zinc dose stays available for absorption. This is chemistry of the reduced form, not a statement about zinc status at ordinary intakes.

The E1 subunit of pyruvate dehydrogenase uses thiamine pyrophosphate bound with a magnesium ion, and it hands the resulting hydroxyethyl group to the lipoamide arm on E2. Magnesium is therefore required one step upstream of where lipoic acid does its work in the same complex. This is textbook enzymology, not a supplementation finding.

Chromium and alpha-lipoic acid are both used in formulas aimed at normal glucose metabolism and act through separate routes, chromium on insulin signalling and lipoic acid on mitochondrial substrate oxidation and glucose transporter translocation. Anyone monitoring blood sugar should account for both being present. No trial of the pair grounds this row.

Berberine activates AMP-activated protein kinase and alpha-lipoic acid has also been described as an AMPK modulator, so the two may act on the same regulatory node. Formulas combining them exist. The additive framing is a caution for anyone tracking glucose values rather than a demonstrated combined effect.

Cinnamon extracts and alpha-lipoic acid appear together in formulas built around normal glucose metabolism. The mechanisms proposed for each differ. This row exists so that the additive direction is recorded, not because a combination study supports it.

Gymnema is a common companion to alpha-lipoic acid in glucose-metabolism formulas and acts through a different proposed route. Stacking several such ingredients means their effects on blood sugar measures may add. That is a monitoring point, not a benefit claim.

Silymarin flavonolignans and dihydrolipoic acid both influence hepatic glutathione handling, from different directions. The liver is where lipoic acid is reduced by lipoamide dehydrogenase in greatest quantity. The pairing is mechanistically coherent and untested as a combination in people.

Taurine is an end product of cysteine oxidation and acts as an intracellular osmolyte and scavenger of hypochlorous acid, a different niche from the dithiol chemistry of lipoic acid. Both are sulfur-containing and both feature in mitochondrial formulas. No combination evidence supports the row.

Alpha-lipoic acid modifies cysteine residues on Keap1, releasing Nrf2 to drive transcription of endogenous antioxidant enzymes, and quercetin is described as acting on the same pathway. Two compounds converging on one transcriptional node is the standard rationale for pairing them. What is measured in such work is enzyme expression, a marker.

Resveratrol is described as acting through sirtuin and AMPK signalling that governs mitochondrial biogenesis, while lipoic acid supports the function of existing mitochondrial dehydrogenase complexes. The pairing targets the same organelle from different angles. It rests on mechanism, not on a combination trial.

Inositol phosphoglycans act as second messengers downstream of the insulin receptor, and lipoic acid has been described as promoting glucose transporter translocation. The two are combined in formulas built around normal glucose handling. Anyone tracking glucose measures should note both are present.